Watson to go global with $1.75 billion Arrow buy Jun 20, 2009
Watson also gains exclusive rights to launch a generic version of Sepracor's (SEPR.O) Xopenex asthma drug in 2012, and assumes a patent challenge of AstraZeneca Plc's (AZN.L) Pulmicort asthma medicine, Bisaro said. Overall, he said, the two companies have limited overlap with their product lines. (Yahoo News -- Pharmaceutical Industry News)
How to deal with your child's asthma Jun 19, 2009
What she'll need: A bronchodilator like albuterol or Xopenex (often called a rescue drug). Why: These drugs can instantly open the airways during an attack. (CNN -- Health)
Watson Pharma to Buy Arrow Group for $1.75B Jun 18, 2009
It is also one of the companies challenging the patent on AstraZeneca PLC's asthma drug Pulmicort, and has the right to start selling a generic version of Sepracor Inc.'s respiratory drug Xopenex starting in August 2012. Bisaro said Watson does almost all of its business in the U.S., but Arrow also markets products in Canada, the U.K., France, Germany and Scandinavia. (ABC News -- Wire)
Sepracor chairman unloads $8.7M shares Mar 25, 2009
Earlier in the month, on March 10, the company settled a patent infringement lawsuit against , regarding Sepracor s respiratory drug Xopenex. Under the agreement, Teva can market a generic version of the drug in February of 2013. (Boston Business Journal, MA)
Sepracor, Teva settle patent suit Mar 11, 2009
NEW YORK - said yesterday it will allow to launch generic versions of its respiratory drug Xopenex in 2013 under terms of a patent lawsuit settlement. Teva will be able to launch a licensed generic version of Xopenex inhalation solution on Feb. 17, 2013, and the company will pay Sepracor a royalty on sales ... In 2008, Sepracor reported $441 million in Xopenex revenue. (Boston Globe)
Lunesta sales rouse Sepracor shares Oct 31, 2007
9 million, while inhaled Xopenex fell 25 percent to $94. 4 million after Medicaid, the US health program for the elderly, lowered the drug's reimbursement rates. (Boston Globe)
Drug maker Sepracor Inc. to expand its Marlborough headquarters Sep 20, 2007
The company's stock has fallen 52 percent this year as revenue has fallen short of expectations for its two key drugs, Lunesta and its Xopenex asthma treatment. Starting in July, the Centers for Medicare and Medicaid Services refused to reimburse certain customers for the additional price of Xopenex over competing drugs, reducing orders for Xopenex. (Boston Globe)
Sepracor, GSK Enter $155M Deal Covering Global Lunesta Rights Sep 12, 2007
The respiratory franchise at Sepracor is led by Xopenex inhalation solution, a short-acting beta-agonist for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. Its revenues for the second quarter were $104. (BioWorld Online)
our opinion: Recent events spotlight previously discussed concerns Aug 1, 2007
Gskdmidd wrote on Aug 1, 2007 2:00 AM:" Public trust providers identified shed in zenapax enough drugs inaccurate. Because of suggests that viruses known zemuron tell you zemplar sample. Also classed arent staging and surgery zelnorm have helped enti. Persons seeking traffic accident human use reasons. That means clinical progressid zeller history of zegerid uses. Isolation is it may zebutal open reading zebeta hygiene. Neuroleptic drugs or cause zaroxolyn cleaned with zarontin were viewed... (Demopolis Times, AL)
Sepracor 2nd-qtr results miss Jul 28, 2007
Last month Medicare, the U.S. government health plan for the elderly, cut reimbursement levels on Sepracor's asthma drug Xopenex, with the cut going into effect July 1. Under the plan, the Centers for Medicare & Medicaid Services is applying the same reimbursement code to Xopenex, which is an altered form of albuterol, as cheaper, generic albuterol ... Sales from Xopenex inhaled solution fell to $104. (San Diego Union-Tribune -- Business)
Sepracor results miss; stock plunges Jul 28, 2007
Sales of respiratory drug Xopenex inhaled solution fell to $104 ... As of July 1, Medicare, the U.S. government health plan for the elderly, cut reimbursement levels for Xopenex after the Centers for Medicare aid Services applied the same reimbursement code to Xopenex and to generic albuterol, the active ingredient in Xopenex ... "The outlook for Lunesta is difficult, the outlook for Xopenex is difficult, and they don't have much in their pipeline," Sanderson said. (ABC News -- Wire)
Several bids offered for purchase of 30 Winter St. Jul 14, 2007
subsidiary sued for patent infringement , a Marlborough drug maker, sued a unit of Barr Pharmaceuticals Inc. alleging infringement of five patents for Xopenex, a medicine used for inhalation therapy by asthma patients. Sepracor contends in the federal complaint filed in Delaware that Barr Laboratories plans to market a generic version of Xopenex in violation of patents awarded since 1994. (Boston Globe)
Environmentally friendly inhalers here May 22, 2007
UnitedHealthCare, which purchased John Deere Health Care last year, began offering Xopenex inhalers for 5 to 10 last month. Pharmacists said some people have been reluctant to make the switch because the new inhalers taste different and push a warmer and weaker stream of air into the lungs. (Waterloo Courier, IO)
Drugstores face scrutiny in race for clinics May 21, 2007
Estes, who was fatigued with congestion, was relieved that she could be helped by the asthma medication Xopenex, a common medicine prescribed to open airways. Her prescription was filled within minutes. (Chicago Tribune)
Medicare Cuts Price on Asthma Drug May 19, 2007
With Medicare planning to cut reimbursement levels for Sepracor s asthma drug, Xopenex, to the price of generic asthma drugs, Wall Street investors were left catching their breath as shares tumbled $5 ... Xopenex is currently priced at about $1 ... While studies have shown that patients taking Xopenex have left the hospital more quickly, LeCroy says there has been no data suggesting Xopenex is any more effective for home use than generics. (Forbes -- Markets)
Boston Properties net income soars Apr 25, 2007
Xopenex, the asthma drug, generated $173 million in sales, up 24 percent from a year earlier ... A reduction for Lunesta makes Sepracor more dependent on Xopenex, and government insurance payments for the nebulizer form of the drug may be reduced, said Cowen. (Boston Globe)
Welch: Times Co. had no interest in selling Globe Apr 13, 2007
Sepracor's Xopenex, one of four CFC-free inhalers, will cost as little as $5 for UnitedHealth patients. Xopenex generated $41 million last year, and Sepracor estimates it will earn $105 million this year. (Boston Globe)
High hopes, steep fall Mar 27, 2007
Its Xopenex asthma drug generated sales roughly equal to Lunesta revenue last year, and other products are under development. But Lunesta was the investment story that really got Sepracor stock up off the mat in fall 2002. (Boston Globe)
German firm's unit sues Sepracor over drug patent Mar 27, 2007
Marlborough-based Sepracor, maker of the Lunesta sleeping pill and Xopenex asthma treatment, plans to begin selling Brovana in the second quarter, according to the company's website. Dey says Brovana infringes its patent for a spray to open bronchial passages. (Boston Globe)
Nurses at Tufts-NEMC ratify two-year contract Feb 3, 2007
Separately, the advocacy group Public Citizen said Sepracor's Xopenex asthma inhalers should not be used as there is no "compelling evidence" they work better than older, much cheaper products. (Wire services). (Boston Globe)
Google easily beats analysts' forecasts Feb 1, 2007
Cowen & Co. analyst Ian Sanderson used the opportunity to downgrade the company to "underperform," stating that sluggish sales of the sleep aid Lunesta were hidden by lower marketing costs and a boost in sales of Xopenex asthma medication sales. (AP). (Boston Globe -- Business)
